Your browser doesn't support javascript.
Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis.
Gupta, Mansi; Ish, Pranav; Malhotra, Nipun.
  • Gupta M; Department of Pulmonary Medicine, Sanjay Gandhi Post-graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, 226014, India. Electronic address: drmansipccm@gmail.com.
  • Ish P; Department of Pulmonary, Critical Care and Sleep Medicine, VMMC and Safdarjung Hospital, New Delhi, India.
  • Malhotra N; Department of Pulmonary, Critical Care and Sleep Medicine, VMMC and Safdarjung Hospital, New Delhi, India.
Indian J Tuberc ; 69(3): 264-267, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1356267
ABSTRACT
The recent guidelines on the Programmatic Management of Drug-Resistant Tuberculosis (DR-TB) in India (PMDT) have been released in March 2021 on World TB Day. The new guidelines have considered emerging diagnostic trends including TrueNat, Xpert Mtb/XDR, Next generation sequencing and evaluation for resistance to newer drugs including Bedaquiline (Bdq) and Delamanid. The emerging therapeutic trends include focus on oral shorter Bdq based regimen with phasing out injectables use. The replacement sequence of drugs for DR-TB have also been updated. Updated definitions for pre-XDR, XDR, culture conversion and default have also been added. These guidelines are a paradigm shift which will make treating DR-TB easier and more efficient especially during the ongoing COVID-19 pandemic crisis.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis, Multidrug-Resistant / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study Limits: Humans Country/Region as subject: Asia Language: English Journal: Indian J Tuberc Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis, Multidrug-Resistant / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study Limits: Humans Country/Region as subject: Asia Language: English Journal: Indian J Tuberc Year: 2022 Document Type: Article